Pharmorubicin CS

Pharmorubicin CS Contraindications





Zuellig Pharma


Full Prescribing Info
Hypersensitivity to epirubicin or any other component of the product, other anthracyclines or anthracenediones.
Situations in which patients should not be treated with intravenous Pharmorubicin are: persisting myelosuppression or severe stomatitis induced by previous drug therapy or radiotherapy; presence of generalised infections; marked liver function impairment; previous history of, or in the presence of, cardiac impairment (severe arrhythmias and cardiomyopathy, previous myocardial infarction); unstable angina pectoris; previous treatments with maximum cumulative doses of mitozantrone, mitomycin C or other anthracyclines, such as doxorubicin or daunorubicin; pregnancy and lactation.
Contraindications for intravesical use are: invasive tumours that have penetrated the bladder wall; urinary infections; inflammation of the bladder; catheterisation problems; haematuria.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in